Monitoring warfarin anticoagulant therapy, especially in patients whose plasma contains lupus anticoagulants that interfere with baseline prothrombin time/international normalized ratio and in patients receiving the drug Argatroban who are being transitioned to warfarin Antithrombotic effect of oral vitamin K antagonists (eg, warfarin) is mediated by reduction in the plasma activity of vitamin K-dependent procoagulant factors II (prothrombin) and X. The intensity of oral anticoagulation therapy with vitamin K antagonists must be monitored and adjusted to a narrow therapeutic range; undermedicating increases the risk of thrombosis, while overmedicating increases the risk of bleeding.
No special preparation is needed for Factor X Assay. Inform your doctor if you are on any medications or have any underlying medical conditions or allergies before undergoing Factor X Assay. Your doctor depending on your condition will give specific instructions.
|UNISEX||All age groups||60 - 140%|